Showing results (931-940 of 2,811) with videos related to
Sort By:
Pageof 282
Expert Opinion on Drug Safety|February 17, 2025
Toxicity spectrum of taxanes: A safety analysis from pre-marketing to post-marketingQiuling Zhao, Zilin Nian, Yimin He, et al.Expert Opinion on Drug Safety|February 14, 2025
Post-marketing safety assessment of constipation drugs: a real-world pharmacovigilance study based on FAERS databaseWenyu Zhang, Hui Wang, Shiwei Yang, et al.Expert Opinion on Drug Safety|February 15, 2025
Updated insights on levetiracetam-associated severe cutaneous adverse reactions: a real-world pharmacovigilance analysisZhanshen Wu, Yang Zhao, Xiangyu Zhang, et al.Expert Opinion on Drug Safety|February 13, 2025
Assessing the risk of acute kidney injury associated with a four-drug regimen for heart failure: a ten-year real-world pharmacovigilance analysis based on FAERS eventsSen Lin, Ruiqi Zhao, Huimin Zhang, et al.Expert Opinion on Drug Safety|February 12, 2025
Postmarketing safety of [177Lu]Lu-PSMA-617 radioligand therapy for prostate cancer: a disproportionality analysis of the FDA adverse event reporting systemYan Zhao, Na Wang, Zhaoqi Zhang, et al.Expert Opinion on Drug Safety|February 20, 2025
Hospital-wide interventions for reducing or preventing in-hospital prescribing errors: a scoping reviewRashudy Fatiha Mahomedradja, Steven Wang, Kim Catherina Eve Sigaloff, et al.Expert Opinion on Drug Safety|February 20, 2025
Incidence and risk of treatment-related fatal adverse events in cancer patients treated with antibody conjugated drugs: a systematic review and meta-analysis of randomized controlled trialsZhaohui Huang, Xinyu Li, Xin Zhou, et al.Expert Opinion on Drug Safety|February 7, 2025
Rivaroxaban to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease: a narrative reviewToufik Abdul-Rahman, Poulami Roy, Ranferi Eduardo Herrera-Calderón, et al.Expert Opinion on Drug Safety|February 10, 2025
Assessment of adverse events of tasimelteon: a real-world pharmacovigilance study based on FAERSTianqi Zuo, Shengzhu Sun, Jingya Yang, et al.Expert Opinion on Drug Safety|February 9, 2025
Adverse event profile of setmelanotide in obesity: an integrated assessment and systematic review using disproportionality analysis, case reports and meta-analysisKannan Sridharan, Gowri SivaramakrishnanPageof 282